RxDoctor Payments Data

Craig Faulks, MD

Orthopaedic Surgery · Washington, DCNPI 1033107883

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.5%), education and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Arthrex at 34.4% of the total. Reporting peaked in 2021 at $1,948 and has fallen 91.2% since, to $172 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in DC, where the typical reported total is $4,260.

$3,991in general payments, 2019–2025

Across 74 payments — averaging $53.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$1K
  • Stryker$570
  • Supreme Orthopedic Systems, LLC$500
  • Ferring Pharmaceuticals Inc.$433
  • Johnson & Johnson$263
  • Smith+Nephew$233
  • plus $618 from 10 others

What the payments were for

  • Travel & lodging$41710%
  • Food & beverage$2,37459%
  • Education$1,20030%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,991 in reported general payments places this provider in the 45th percentile of 46 orthopaedic surgery providers in District of Columbia.

See all orthopaedic surgery providers in District of Columbia

Medicare billing

Part B allowed, 2024
$323,291
Medicare patients
280
Services billed
9,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib220$5,066
Methylprednisolone51$385
Meloxicam41$129
Oxycodone Hcl21$73
Amoxicillin19$53

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →